Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-08-28 |
2024-06 |
0 |
2.16 |
N/A |
N/A |
2024-05-30 |
2024-03 |
0 |
-2.76 |
N/A |
N/A |
2024-04-04 |
2023-12 |
0 |
-11.76 |
N/A |
N/A |
2023-11-22 |
2023-09 |
0 |
-2.88 |
N/A |
N/A |
2023-08-09 |
2023-06 |
0 |
-11.4 |
N/A |
N/A |
2023-06-01 |
2023-03 |
0 |
-13.09 |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2023-07-23 |
Maxim Group |
Upgrade |
Hold |
Buy |
2022-08-07 |
Maxim Group |
Downgrade |
Buy |
Hold |
2022-08-07 |
Canaccord Genuity |
Downgrade |
Buy |
Hold |
2022-05-17 |
Raymond James |
Downgrade |
Outperform |
Market Perform |
2022-05-02 |
HC Wainwright & Co. |
Downgrade |
Buy |
Neutral |
2022-05-02 |
Raymond James |
Upgrade |
|
Outperform |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
BVF Inc. |
89.85K |
268.66K |
0.36% |
2023-06-29 |
Susquehanna International Group, LLP |
25.60K |
76.54K |
0.10% |
2023-06-29 |
Millennium Management Llc |
14.91K |
44.57K |
0.06% |
2023-06-29 |
Morgan Stanley |
12.50K |
37.37K |
0.05% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Delaware Group Equity Fds IV-Delaware Healthcare Fund |
20.40K |
61.00K |
0.08% |
2023-05-30 |
Fidelity NASDAQ Composite Index Fund |
1.81K |
8.36K |
0.01% |
Split |
Date |
1 : 12 |
2024-08-30 |
1 : 15 |
2023-05-15 |